The addition of EGFRxCD3 sBiTE was shown to enhance anti-tumor activity of the transfected cells and engage also non gene-modified T cells, in vitro and in vivo.[47] Also, an anti-MUC16 CAR construct combined with a secretable anti-WT1 BiTE has been proposed recently [52]. The gene discussed is MUC16; the disease is neoplasm.